1.78

9.20% 0.15

After Hours: 1.59 -0.19 -10.67%

Rein Therapeutics Inc (RNTX)

Overview News Price History Discussions Forecast

Rein Therapeutics Inc stock is traded at $1.78, with a volume of 172.80K. It is up +9.20% in the last 24 hours and up +36.92% over the past month. Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Previous Close:

$1.63

Open:

$1.63

24h Volume:

172.80K

Relative Volume:

1.50

Market Cap:

$49.91M

Revenue:

Net Income/Loss:

$-49.87M

P/E Ratio:

-0.9063

EPS:

-1.964

Net Cash Flow:

$-19.36M

1W Performance:

+13.38%

1M Performance:

+36.92%

6M Performance:

+36.92%

1Y Performance:

+3.49%

1-Day Range:

$1.555

$1.83

1-Week Range:

$1.42

$1.83

52-Week Range:

$1.02

$2.40

Rein Therapeutics Inc Stock (RNTX) Company Profile

Name

Rein Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(737) 802-1989

Address

12407 N. MOPAC EXPY., AUSTIN

Employee

Twitter

Next Earnings Date

2026-04-06

Latest SEC Filings

RNTX's Discussions on Twitter

Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNTX Rein Therapeutics Inc	1.78	45.70M	0	-49.87M	-19.36M	-1.964
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-25	Initiated	H.C. Wainwright	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-24-17	Initiated	BofA/Merrill	Buy
Jul-24-17	Initiated	Jefferies	Buy
Jul-24-17	Initiated	William Blair	Outperform

Rein Therapeutics Inc Stock (RNTX) Latest News

Apr 11, 2026

Why Rein Therapeutics Inc. stock is a must watch in 20262026 Earnings Surprises & Stock Timing and Entry Methods - bollywoodhelpline.com

Apr 11, 2026

Apr 08, 2026

FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst - defenseworld.net

Apr 08, 2026

Apr 07, 2026

PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI

Apr 07, 2026

Apr 02, 2026

RNTX Forecast, Price Target & Analyst Ratings | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill

Apr 02, 2026

Mar 31, 2026

Rein 2026 10-K Report: Business Overview, Risk Factors, Pipeline, Competition, and Strategic Partnerships - Minichart

Mar 27, 2026

Mar 26, 2026

Rein Therapeutics 10-K: $0 Revenue, $0 Gross Profit; Net Loss $49.9M - TradingView — Track All Markets

Mar 26, 2026

Rein Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 26, 2026

Rein Therapeutics (NASDAQ: RNTX) 10-K shifts focus to LTI-03 and flags 2026 funding needs - stocktitan.net

Mar 26, 2026

Mar 25, 2026

Rein Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 25, 2026

Mar 20, 2026